<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="107637">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01981863</url>
  </required_header>
  <id_info>
    <org_study_id>Fibrinolysis</org_study_id>
    <nct_id>NCT01981863</nct_id>
  </id_info>
  <brief_title>Fibrinolysis Before Cardiopulmonary Bypass?</brief_title>
  <official_title>Fibrinolysis Before Cardiopulmonary Bypass?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is common practice to use antifibrinolytic agents before and during cardiopulmonary
      bypass. They are not without side effects. The investigators want to show that there is no
      proof of fibrinolysis in standard sternotomy cardiac surgery patients before cardiopulmonary
      bypass, and that antifibrinolytic agents should only be started on cardiopulmonary bypass.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double-blind, placebo controlled, prospective study in two groups of 20 patients. Control
      group (A) receives standard Epsilonaminocaproic acid treatment before cardiopulmonary bypass
      (10 gr loading dose, and 1 gr/hr infusion), and second group (B) receives placebo. Before
      start of Epsilonaminocaproic acid/placebo, D-Dimers and Thromboelastography are measured,
      repeated just before full heparinization. After heparinization group A receives placebo, and
      group B Epsilonaminocaproic acid.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Di-Dimer increase before cardiopulmonary bypass</measure>
    <time_frame>8 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Significant increase of Di-dimer between preoperative value and value immediately before cardiopulmonary bypass in cardiac surgery patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Value of Thromboelastography as monitor of fibrinolysis</measure>
    <time_frame>8 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Thromboelastography shows theoretically fibrinolysis if present, but the relationship with the level of increase of Di-dimers is unknown.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Fibrinolysis before cardiopulmonary bypass?</measure>
    <time_frame>8 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Pathologic Fibrinolysis</condition>
  <arm_group>
    <arm_group_label>Epsilonaminocaproic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One arm: Epsilonaminocaproic acid 10 gr IV, followed by 1 gr/hr infusion Second arm: placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Antifibrinolytic activity</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: same IV volume as experimental arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epsilonaminocaproic acid</intervention_name>
    <description>One group receives Epsilonaminocaproic acid, 10 gr IV bolus, followed by 1 gr/hr. Second group receives placebo.</description>
    <arm_group_label>Epsilonaminocaproic acid</arm_group_label>
    <other_name>Amicar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered in same volume as in experimental arm.</description>
    <arm_group_label>Placebo, Antifibrinolytic activity</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All adult patients, undergoing first time sternotomy for Coronary artery bypass
             grafting/Aortic valve replacement/aortic surgery

        Exclusion Criteria:

          -  Resternotomy, renal insufficiency, deep hypothermia, age &lt; 18 yrs
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pieter JA Van der Starre, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pieter Van der Starre, MD. PhD</last_name>
    <email>pieterva@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford Hospital &amp; Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pieter Van der Starre, MD, PhD</last_name>
      <email>pieterva@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Pieter Van der Starre, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 5, 2013</lastchanged_date>
  <firstreceived_date>September 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cardiac surgery</keyword>
  <keyword>cardiopulmonary bypass</keyword>
  <keyword>fibrinolysis</keyword>
  <keyword>thromboelastography</keyword>
  <keyword>D-Dimers</keyword>
  <keyword>antifibrinolytic agents</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antifibrinolytic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
